Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression

Psychiatry Research

Volumn 239, Issue , 2016, Pages 85-91

  Schmidt, Frank M ^a   Schröder, Thomas ^a   Kirkby, Kenneth C ^b   Sander, Christian ^a   Suslow, Thomas ^a   Holdt, Lesca M ^c   Teupser, Daniel ^c   Hegerl, Ulrich ^a   Himmerich, Hubertus ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antidepressant treatment prediction; BDI II; Biomarker; Depressive symptoms; HAMD 17; Immunity; Inflammation

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; IL10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SELF EVALUATION; SYMPTOM; BLOOD; DEPRESSIVE DISORDER, MAJOR; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84960090416     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2016.02.052     Document Type: Article

References (56)

1. Angstman K.B., Wade T.W., Dejesus R.S., Rundell J.R., Altrichter P.M. Patient body Mass index does not predict six-month clinical outcome of depression managed under collaborative care. J. Prim. Care Community Health 2013, 4:119-123.
2. Baune B.T., Konrad C., Grotegerd D., Suslow T., Ohrmann P., Bauer J., Arolt V., Heindel W., Domschke K., Schöning S., Rauch A.V., Sehlmeyer C., Kugel H., Dannlowski U. Tumor necrosis factor gene variation predicts hippocampus volume in healthy individuals. Biol. Psychiatry 2012, 72:655-662.
3. Beck A.T., Steer R.A., Brown G.K. BDI-II, Beck Depression Inventory: Manual 1996, Harcourt Brace, Boston. 2nd edition.
4. Berk M., Williams L.J., Jacka F.N., O'Neil A., Pasco J.A., Moylan S., Allen N.B., Stuart A.L., Hayley A.C., Byrne M.L., Maes M. So depression is an inflammatory disease, but where does the inflammation come from? BMC. Medicine 2013, 11:200.
5. Brambilla F., Monteleone P., Maj M. Interleukin-1β and tumor necrosis factor-αin children with major depressive disorder or dysthymia. J. Affect. Disord. 2004, 78:273-277.
6. Dahl J., Ormstad H., Aass H.C., Malt U.F., Bendz L.T., Sandvik L., Brundin L., Andreassen O.A. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014, 45:77-86.
7. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
8. Dantzer R. Cytokine, sickness behavior, and depression. Immunol. Allergy Clin. N. Am. 2009, 29:247-264.
9. De Simoni M.G., Terreni L., Chiesa R., Mangiarotti F., Forloni G.L. Interferon-gamma potentiates interleukin (IL)-6 and tumor necrosis factor-alpha but not IL-1beta induced by endotoxin in the brain. Endocrinology 1997, 138:5220-5226.
10. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctôt K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
11. Eller T., Aluoja A., Maron E., Vasar V. Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. Medicina 2009, 45:971-977.
12. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:445-450.
13. Felger J.C., Lotrich F.E. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246:199-229.
14. Frodl T., Carballedo A., Hughes M.M., Saleh K., Fagan A., Skokauskas N., McLoughlin D.M., Meaney J., O'Keane V., Connor T.J. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl. Psychiatry 2012, 13(2):e88.
15. Gobinath A.R., Mahmoud R., Galea L.A. Influence of sex and stress exposure across the lifespan on endophenotypes of depression: focus on behavior, glucocorticoids, and hippocampus. Front. Neurosci. 2015, 8:420.
16. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
17. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
18. Himmerich H., Binder E.B., Künzel H.E., Schuld A., Lucae S., Uhr M., Pollmächer T., Holsboer F., Ising M. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol. Psychiatry 2006, 60:882-888.
19. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., Gedrich K., Kloiber S., Lucae S., Ising M., Uhr M., Holsboer F., Pollmächer T. Depression, comorbidities and the TNF-alpha system. Eur. Psychiatry 2008, 23:421-429.
20. Himmerich H., Milenović S., Fulda S., Plümäkers B., Sheldrick A.J., Michel T.M., Kircher T., Rink L. Regulatory T cells increased while IL-1β decreased during antidepressant therapy. J. Psychiatr. Res. 2010, 44:1052-1057.
21. Himmerich H., Wranik D.W. Choice of treatment with antidepressants: influencing factors. Curr. Pharm. Des. 2012, 18:5958-5975.
22. Hinze-Selch D., Schuld A., Kraus T., Kühn M., Uhr M., Haack M., Pollmächer T. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline OR paroxetine. Neuropsychopharmacology 2000, 23:13-19.
23. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
24. Huang, C., Chen, J.H., 2014. Meta-Analysis of the Factor Structures of the Beck Depression Inventory-II. Assessment, pii: 1073191114548873.
25. Janssen D.G., Caniato R.N., Verster J.C., Baune B.T. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol. 2010, 25:201-215.
26. Kim S.Y., Kim J.M., Kim S.W., Shin I.S., Park M.H., Yoon J.H., Choi C., Yoon J.S. Associations between plasma cytokines and depressive mood in patients with breast cancer. Int. J. Psychiatry Med. 2012, 43:1-17.
27. Kraus T., Haack M., Schuld A., Hinze-Selch D., Koethe D., Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002, 35:220-225.
28. Krügel U., Fischer J., Radicke S., Sack U., Himmerich H. Antidepressant effects of TNF-α blockade in an animal model of depression. J. Psychiatr. Res. 2013, 47:611-666.
29. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
30. Lichtblau N., Schmidt F.M., Schumann R., Kirkby K.C., Himmerich H. Cytokines as biomarkers in depressive disorder: current standing and prospects. Int. Rev. of Psychiatry 2013, 25:592-603.
31. Lopresti A.L., Drummond P.D. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45:92-99.
32. Maes M., Berk M., Goehler L., Song C., Anderson G., Gałecki P., Leonard B. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012, 10:66.
33. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9:853-858.
34. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferring receptor in major depression. J. Affect. Disord. 1995, 34:301-309.
35. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 2009, 24:27-53.
36. Munzer A., Sack U., Mergl R., Schönherr J., Petersein C., Bartsch S., Kirkby K.C., Bauer K., Himmerich H. Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins 2013, 5:2227-2240.
37. Petersein C., Sack U., Mergl R., Schönherr J., Schmidt F.M., Lichtblau N., Kirkby K.C., Bauer K., Himmerich H. Impact of lithium alone and in combination with antidepressants on cytokine production in vitro. J. Neural Transm. 2015, 122:109-122.
38. Reichenberg A., Kraus T., Haack M., Schuld A., Pollmächer T., Yirmiya R. Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF α and IL-6 secretion. Psychoneuroendocrinology 2002, 27:945-956.
39. Schmidt F.M., Lichtblau N., Minkwitz J., Chittka T., Thormann J., Kirkby K.C., Sander C., Mergl R., Faßhauer M., Stumvoll M., Holdt L.M., Teupser D., Hegerl U., Himmerich H. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J. Psychiatr. Res. 2014, 55:29-34.
40. Schmidt F.M., Kirkby K.C., Himmerich H. The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression-report of two cases. Psychiatr. Danub. 2014, 26:288-290.
41. Schmidt F.M., Weschenfelder J., Sander C., Minkwitz J., Thormann J., Chittka T., Mergl R., Kirkby K.C., Faßhauer M., Stumvoll M., Holdt L.M., Teupser D., Hegerl U., Himmerich H. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One 2015, 10:e0121971.
42. Schmidt F.M., Nowak C., Kratzsch J., Sander C., Hegerl U., Schönknecht P. Melanin-concentrating Hormone (MCH) in major depressive disorder during antidepressant therapy. J. Affect. Disord. 2015, 180:207-213.
43. Schneibel R., Brakemeier E.L., Wilbertz G., Dykierek P., Zobel I., Schramm E. Sensitivity to detect change and the correlation of clinical factors with the Hamilton depression rating scale and the beck depression inventory in depressed inpatients. Psychiatry Res. 2012, 198:62-67.
44. Serafini G., Pompili M., Elena Seretti M., Stefani H., Palermo M., Coryell W., Girardi P. The role of inflammatory cytokines in suicidal behavior: a systematic review. Eur. Neuropsychopharmacol. 2013, 23(12):1672-1686.
45. Shelton M.M., Schminkey D.L., Groer M.W. Relationships among prenatal depression, plasma cortisol, and inflammatory cytokines. Biol. Res. for. Nursing 2015, 17:295-302.
46. Simon N.M., McNamara K., Chow C.W., Maser R.S., Papakostas G.I., Pollack M.H., Nierenberg A.A., Fava M., Wong K.K. A detailed examination of cytokine abnormalities in major depressive disorder. Eur. Neuropsychopharmacol. 2008, 18:230-233.
47. Stratmann M., Konrad C., Kugel H., Krug A., Schöning S., Ohrmann P., Uhlmann C., Postert C., Suslow T., Heindel W., Arolt V., Kircher T., Dannlowski U. Insular and hippocampal gray matter volume reductions in patients with major depressive disorder. PLoS One 2014, 9:e102692.
48. Swaab D.F., Bao A.M., Lucassen P.J. The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev. 2005, 4:141-194.
49. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O'Brien J.T. Increase in interleukin-1beta in late-life depression. Am. J. Psychiatry 2005, 162:175-177.
50. Toups M.S., Myers A.K., Wisniewski S.R., Kurian B., Morris D.W., Rush A.J., Fava M., Trivedi M.H. Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. Psychosom. Med. 2013, 75:863-872.
51. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahrei s A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
52. Uher R., Tansey K.E., Dew T., Maier W., Mors O., Hauser J., Dernovsek M.Z., Henigsberg N., Souery D., Farmer A., McGuffin P. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 2014, 171:1278-1286.
53. Williams J.B. A structured interview guide for the Hamilton depression rating scale. Arch. Gen. Psychiatry 1988, 45:742-747.
54. Wittchen, H.U., Zaudig, M., Fydrich, T., 1997. SKID Strukturiertes Klinisches Interview für DSM-IV (Achse I und II). Hogrefe, Göttingen.
55. Wong H.L., Pfeiffer R.M., Fears T.R., Vermeulen R., Ji S., Rabkin C.S. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomark. Prev. 2008, 17:3450. 2456.
56. Yoshimura R., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Ueda N., Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- OR SNRI-refractory depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:722-726.